Can-Fite reports two updates: psoriasis enrollment milestone and pancreatic cancer safety data

Can-Fite BioPharma disclosed two clinical updates in early July 2026 filings with the SEC.

On July 6, 2026, the company said it had completed enrolment of the first 247 patients in its pivotal Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis¹. It said the study has now reached the pre-specified interim analysis stage under a protocol agreed with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)¹. Results are expected during Q4 2026/Q1 2027.¹ The trial's study is a randomized, double-blind, placebo-controlled Phase 3 trial in which patients are treated with 3 mg Piclidenoson tablets or placebo administered orally twice daily¹, with co-primary efficacy objectives of PASI 75 response and sPGA of 0 or 1 at Week 16¹.

Separately, on July 1, 2026, Can-Fite reported findings from a Phase 2a trial of Namodenoson in advanced pancreatic ductal adenocarcinoma. The open-label study enrolled 20 patients who had progressed following standard therapies, with fourteen receiving Namodenoson as third-line treatment, five as second-line, and one as fourth-line². The company said Namodenoson was well tolerated, with a safety profile consistent with prior clinical trials².

Among eight evaluable third-line patients, median overall survival exceeded 5 months, 62.5% survived five months or longer, 37.5% survived seven months or longer, two patients remained alive at the data cutoff, and progression-free survival extended beyond seven months in some cases². Notably, one of five second-line patients remained alive more than 18 months after starting Namodenoson, the longest survivor in the study².

Based on these results, Can-Fite said it plans to advance Namodenoson into a Phase 2b combination study with chemotherapy².